We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+41.17%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.01B
AUM Growth
+$219M
Cap. Flow
+$20.1M
Cap. Flow %
1.99%
Top 10 Hldgs %
55.14%
Holding
55
New
15
Increased
6
Reduced
11
Closed
15

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$36.3M
2
GNFT
Genfit
GNFT
+$28.4M
3
EPZM
Epizyme, Inc
EPZM
+$24.3M
4
PTCT icon
PTC Therapeutics
PTCT
+$19.8M
5
CTMX icon
CytomX Therapeutics
CTMX
+$14.2M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$24.7M
2
CYTK icon
Cytokinetics
CYTK
+$20.1M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$17.6M
4
PBYI icon
Puma Biotechnology
PBYI
+$14.7M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$14.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
51
Voyager Therapeutics
VYGR
$183M
– –
-365,132
Closed -$3.43M
ITCI
52
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-400,000
Closed -$4.56M
VIRX
53
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-9,085
Closed -$132K
AMAG
54
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-664,681
Closed -$10.1M
ONCE
55
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-630,600
Closed -$24.7M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Great Point Partners held 55 positions worth $1.01B, up 28% from $791M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Great Point Partners's Q1 2019 filing shows 15 new, 6 increased, 11 reduced and 15 closed positions. Its largest new stake was Ascendis Pharma A/S: 415,000 shares worth $48.8M. The largest sale was Spark Therapeutics, Inc. Common Stock, an estimated $24.7M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier.

  • Great Point Partners's largest Q1 2019 buy was Ascendis Pharma A/S: 415,000 shares worth $48.8M.
  • Great Point Partners added most to PTC Therapeutics in Q1 2019, an estimated $19.8M increase.
  • Great Point Partners's biggest Q1 2019 reduction was Acadia Pharmaceuticals, cutting an estimated $17.6M.
  • Great Point Partners fully exited Spark Therapeutics, Inc. Common Stock in Q1 2019, selling an estimated $24.7M.
  • Great Point Partners's ten largest holdings make up 55% of its $1.01B portfolio in Q1 2019.
  • Great Point Partners opened 15 new positions and closed 15 in Q1 2019.
  • Great Point Partners's portfolio value rose 28% quarter-over-quarter to $1.01B.

Based on Great Point Partners's 13F filing for Q1 2019, filed 14 May 2019.